Results 41 to 50 of about 179,970 (275)

Treatment of postmenopausal osteoporosis [PDF]

BMJ, 2005
Has improved owing to the availability of many drugs that prevent fractures Osteoporosis is characterised by bone fragility due to low bone mass and modifications of the internal bone structure, with alterations of its microarchitecture. Of various fragility fractures that represent the major complication of the disease, vertebral and hip fractures ...
openaire   +4 more sources

Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis

, 2010
Bisphosphonates are the leading drugs for the treatment of osteoporosis. In ­randomized controlled trials (RCTs), alendronate, risedronate, and zoledronate have shown to reduce the risk of vertebral, nonvertebral, and hip fractures, whereas RCTs with ...
Graham Russell, Cooper, Cyrus, Ebetino, F. Hal, Cooper, C, Russell, RG, Pazianas, Michael, Ebetino, FH, Russell, R. Graham G., Pazianas, M   +8 more
core   +1 more source

Overview on postmenopausal osteoporosis and periodontitis: The therapeutic potential of phytoestrogens against alveolar bone loss

Frontiers in Pharmacology, 2023
Osteoporosis and periodontitis are two major chronic diseases of postmenopausal women. The association between these two diseases are evident through systemic bone loss and alveolar bone loss.
Putri Ayu Jayusman, Nurrul Shaqinah Nasruddin, Badiah Baharin, Nurul ‘Izzah Ibrahim, Haryati Ahmad Hairi, Ahmad Nazrun Shuid   +5 more
doaj   +1 more source

Ubiquitination of ACSL4 by Parkin Suppresses Ferroptosis and Rescues Glucocorticoid‐Induced Bone Loss

Advanced Science, EarlyView.
GCs reduce Parkin, leading to ACSL4 accumulation and PUFA‐phospholipid‐driven ferroptosis in BMSCs, which impairs osteogenesis and promotes adipogenesis, causing GIOP. Parkin restoration (via OE‐Parkin or Parkin‐LNP@DSS6) ubiquitinates and degrades ACSL4, inhibiting ferroptosis, rescuing bone formation, and rescues GIOP bone loss.
Li‐jiang Han, Jian‐sen Miao, Yi‐feng Shi, Yi‐ting Tu, Yu‐zhe Lin, Lin‐Jie Chen, Bing‐hao Lin, Hua‐lin Li, Xuan‐qi Zheng, Hong‐qiang Wu, Hai‐xiao Liu, Lei Yang, Ai‐min Wu, Zhen Lin, Jian Xiao, Gang Zheng, Chen Jin   +16 more
wiley   +1 more source

Similarities in Acquired Factors Related to Postmenopausal Osteoporosis and Sarcopenia

Journal of Osteoporosis, 2011
Postmenopausal population is at increased risk of musculoskeletal impairments. Sarcopenia and osteoporosis are associated with significant morbidity and social and health-care costs.
Joonas Sirola, Heikki Kröger
doaj   +1 more source

Osteoporosis knowledge and beliefs among postmenopausal women: A cross-sectional study from a teaching hospital in southern India

Journal of Family Medicine and Primary Care, 2019
Objectives: Osteoporosis continues to be underrecognized in many parts of India. This study was undertaken to assess the level of knowledge of osteoporosis among postmenopausal women referred for a dual-energy X-ray absorptiometry (DXA) scan in a ...
Manickavasagam Senthilraja, Kripa Elizabeth Cherian, Felix K Jebasingh, Nitin Kapoor, Thomas Vizhalil Paul, Hesarghatta Shyamasunder Asha   +5 more
doaj   +1 more source

YAP1‐Driven Pathogenic Fibro‐Adipogenic Progenitors Secrete IL‐6 and FGF21 to Mediate Muscle‐Bone Crosstalk and Promote Bone Loss

Advanced Science, EarlyView.
Fibro‐adipogenic progenitors (FAPs) in atrophic muscle undergo YAP1‐driven pathogenic activation, secreting IL‐6 and FGF21 as bone‐catabolic myokines that mediate muscle‐bone crosstalk and promote bone loss. Genetic or pharmacological targeting of this YAP1‐FAP‐myokine axis rescues skeletal deterioration, identifying FAP‐derived myokines as therapeutic
Xiaoyu Cai, Tao Xu, Rui Ma, Weikun Meng, Shutao Gao, Yakefu Abulizi, Alafate Kahaer, Chuanhui Xun, Maierdan Maimaiti, Rui Cao, Weidong Liang, Polati Maimaiti, Qiang Deng, Jun Sheng, Ting Wang, Mingchong Liu, Weibin Sheng   +16 more
wiley   +1 more source

The Impact of Vertebral Fractures on Quality of Life in Postmenopausal Osteoporosis

, 2011
Aim: The aim of this study was to investigate the impact of vertebral fractures on quality of life in postmenopausal osteoporosis. Material and Methods: 158 postmenopausal women were included in this study.
Hakan Nur, N. Füsun Toraman
core   +1 more source

WTAP Transcriptional Suppression by KLF9 Drives Osteoclastogenesis via M6A‐Mediated Regulation of CSF1R Signaling in Estrogen‐Deficient Osteoporosis

Advanced Science, EarlyView.
Scheme of the KLF9/WTAP/YTHDF2/m6A/CSF1R regulatory axis in osteoclastogenesis and estrogen‐deficient osteoporosis. WTAP‐mediated m6A modification of Csf1r mRNA governs osteoclastogenesis via a YTHDF2‐mediated pathway. Pathological upregulation of KLF9 drives Wtap transcription, leading to increased m6A deposition on the 3’‐UTR of Csf1r mRNA.
Chen Shen, Xin Liu, Gaoran Ge, Li Xu, Ziyu Zhang, Chang Lv, Hao Xu, Wenhao Li, Yi Qin, Qifeng Sheng, Qihan Wang, Hongxia Li, Jun Zhou, Huilin Yang, Dechun Geng   +14 more
wiley   +1 more source

Fracture Risk Associated With Long-Term Discontinuation of Postmenopausal Osteoporosis Treatment: A French Population-Based Study Using National Claims Data (Système National des Données de Santé). [PDF]

ACR Open Rheumatol
Objective This retrospective cohort study evaluated the long‐term discontinuation (LTD) of osteoporosis treatments in postmenopausal women in France and associated fracture risk and economic burden. Methods From the national French health care database (Système National des Données de Santé), we included postmenopausal women aged ≥60 years initiating ...
Lajoinie A, Benmerad M, Laborey M, Samama P, Désaméricq G, Chelbani L, Briot K.   +6 more
europepmc   +2 more sources